Indication intelligence, analysis and sector perception

Histogenics (HSGX) publication of peer reviewed in the Journal of Orthopaedic Research

March 9, 2017 1:00pm

Entitled Mechanical properties and structure-function relationships of Human Chondrocyte-Seeded Cartilage constructs after In Vitro culture

HSGX is UP +$0.08 to $1.82

The initial data were presented at the Orthopaedic Research Society annual meeting in 3/16 and are based on a long-standing cooperative research agreement between Histogenics and Cornell.

The Bottom Line: The results of the study suggest that in vitro cartilage constructs, or tissue implants, produced using a process that is designed to mimic that of NeoCart exhibited mechanical properties prior to implantation approaching such properties of native cartilage.

Specifically, the results of the study indicate that a combination of cells, scaffold and engineering play an important role in the development of tissue engineered-cartilage implants, such as NeoCart, and the maturation of such implants, leads to improved biological and mechanical properties.

BUY, an advancing P3 trial, cash and a solid management team versus some…!

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

1 hour 25 min ago
RegMed Investors (RMi) Closing Bell: declining threads extend

9 hours 53 min ago
RegMed Investors’ (RMi) pre-open: who knows where share pricing goes as the sword of Damocles hangs overhead

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.